Mus vs Tuvalu: The number of people with susceptibility test result for rifampicin
Mus
100
in 2021
Tuvalu
100
in 2021
Mus rank
1st
Tuvalu rank
2nd
The number of people with susceptibility test result for rifampicin over time
- Mus
- Tuvalu
How they compare
Mus currently reports 100 against 100 in Tuvalu, a difference of 0.
The two have swapped places 4 times across 5 shared years of data; in 2017 it was Tuvalu ahead.
Mus ranks 1st and Tuvalu ranks 2nd of 2 regions.
Across the 2 decades both report, Mus averaged higher in 1 and Tuvalu in 1.
Head to head by decade
| Decade | Mus | Tuvalu | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 100 | 114.29 | 14.29 | Tuvalu |
| 2020s | 100 | 96.88 | 3.12 | Mus |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Mus or Tuvalu?
- Mus, at 100 against 100 in Tuvalu as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Mus and Tuvalu?
- 0, with Mus ahead.
- How many years of comparable data are there for Mus and Tuvalu?
- 5 years are reported by both, from 2017 to 2021.
- How do Mus and Tuvalu rank globally for the number of people with susceptibility test result for rifampicin?
- Mus ranks 1st and Tuvalu ranks 2nd of 2 regions.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.